EVMN
Evommune, Inc. (NYSE)
Healthcare — Biotechnology
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Buy
1.7 / 5
7 analysts
$11.42
$-0.80 (-6.55%)
Target:
$35.86
(214.0%)
Sign in to add EVMN to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $461.76M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.96 |
| EPS (TTM) | $-2.11 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -44.95% |
| Debt/Equity | 2.99 |
| Recommendation | Buy 1.7 |
| Analyst Target | $35.86 |
| Analysts | 7 |
| Indexes | NYSE |
Technical Indicators
| RSI (14) | 32.4 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $33.20 |
| 52-Week Low | $12.65 |
| 50-Day Avg | $22.27 |
| 200-Day Avg | $21.89 |
| Avg Volume | 767.6K |
| Volume | 325.6K |
Performance Analysis
BULLISHEVMN shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($12.65), which could present a value opportunity.
~
RSI at 32.4 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Buy" from 7 analysts.
+
Average analyst target of $35.86 implies 214.0% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:08 UTC
Back to Screener Export Report